Use of sodium-glucose cotransporter 2 inhibitors was linked to significantly reduced risk for serious liver events for ...

With an estimated 1.5 million new cases and 397,000 deaths worldwide, prostate cancer is the world's second most frequent ...

LAS VEGAS — In this video from Clinical Trials at the Summit, Lejla Vajzovic, MD, FASRS, of Duke Eye Center, discusses tyrosine kinase inhibitors and gene therapy as different approaches for ...

Exelixis, Inc. (Nasdaq: EXEL) today announced positive topline results from the STELLAR-303 phase 3 pivotal trial in which zanzalintinib in combination with ...

I don’t think it’s a slam dunk.” Johnson said her enthusiasm about SC PD-1/PD-L1 inhibitors is tempered after speaking with the pharmacist at her practice, SCRI Oncology Partners.

Initially used for blood glucose control, the medications reduce cardiovascular events and mitigate heart failure hospitalization, regardless of diabetes status.

The SGLT2 inhibitor empagliflozin (Jardiance) reduced the risk of creatinine increases and acute kidney injury (AKI) even in those with an early dip in estimated glomerular filtration rate (eGFR ...

Merck & Co.’s ambition to get the first oral PCSK9 inhibitor to market came one step closer this morning as the pharma unveiled a pair of phase 3 wins for enlicitide decanoate in patients with ...

Patients with BRCA -altered uterine leiomyosarcoma (LMS) treated with PARP inhibitors demonstrated encouraging outcomes, including an overall response rate (ORR) of 46%, a clinical benefit rate (CBR) ...

Janus kinase (JAK) inhibitors, including ruxolitinib cream and abrocitinib, demonstrate strong efficacy in atopic dermatitis (AD), offering viable alternatives to systemic therapies.

A study of biologic-naive patients with psoriasis or PsA found that IL-17, IL-12/23, and IL-23 inhibitors have cardiovascular and thrombotic risk profiles comparable with those of TNF inhibitors.